Current Trends of Combination Therapy in Chronic Hepatitis B Management in China

<p>In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still w...

Full description

Saved in:
Bibliographic Details
Main Author: En-Qiang Chen (Author)
Format: Book
Published: Archives of Hepatitis Research - Peertechz Publications, 2015-08-28.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_ahr_000001
042 |a dc 
100 1 0 |a En-Qiang Chen  |e author 
245 0 0 |a Current Trends of Combination Therapy in Chronic Hepatitis B Management in China 
260 |b Archives of Hepatitis Research - Peertechz Publications,   |c 2015-08-28. 
520 |a <p>In the past decade, five oral nucleos(t)ide analogs and two formulations of pegylated interferon alpha have been approved for the treatment of chronic hepatitis B (CHB). Due to low personal income and inadequate health care system, low-to-moderate genetic barrier antiviral drugs are still widely used in China, which brings increased suboptimal response, viral relapse and resistance in reallife clinical  practice. Combination therapy is a relative good approach to deal with these dilemma in Chinese CHB patients, and the strategies include de novo combination, rescue combination therapy, and optimized combination therapy. At present, combination therapy could be sonsidered for those who have suboptimal response to antiviral drugs, at high risk of complications in the event of virological breakthrough/rebound, or already with drug-resistant hepatitis B virus infection.</p> 
540 |a Copyright © En-Qiang Chen et al. 
546 |a en 
655 7 |a Review Article  |2 local 
856 4 1 |u https://doi.org/10.17352/ahr.000001  |z Connect to this object online.